Discontinuation of new hepatitis C drugs among Medicare patients

Keyphrases

• Medicaid Patients 100%
• Hepatitis C Drugs 100%
• Low-income Subsidy 100%
• Direct-acting Antivirals 85%
• Direct-acting Antiviral Therapy 71%
• Patient Characteristics 28%
• Chronic Hepatitis C 28%
• Clinical Trials 14%
• Hepatitis C 14%
• Hispanic 14%
• Medicare Beneficiaries 14%
• Black Women 14%
• Dasabuvir 14%
• Retrospective Analysis 14%
• Adjusted Odds Ratio 14%
• Medicare Claims 14%
• White Patients 14%
• Hispanic Patients 14%
• Index Score 14%
• Expected Duration 14%
• Multivariable Logistic Regression 14%
• Discontinuation Rate 14%
• Comorbidity Index 14%
• As(III) 14%
• Resource Waste 14%
• Patient Risk 14%
• High-risk Comorbidities 14%
• Fee-for-service Medicare 14%
• Ombitasvir/paritaprevir/ritonavir 14%
• Elbasvir/grazoprevir 14%

Medicine and Dentistry

• Medicare 100%
• Hepatitis C 100%
• Antiviral Drug 100%
• Antiviral Therapy 83%
• Patient Characteristics 33%
• Chronic Hepatitis C 33%
• Clinical Trial 16%
• Logistic Regression Analysis 16%
• Ritonavir 16%
• Dasabuvir 16%
• Paritaprevir 16%
• Ombitasvir 16%
• Comorbidity 16%
• Odds Ratio 16%
• Elbasvir 16%
• Grazoprevir 16%

Pharmacology, Toxicology and Pharmaceutical Science

• Antiviral Drug 100%
• Hepatitis C 100%
• Antiviral Therapy 83%
• Chronic Hepatitis C 33%
• Clinical Trial 16%
• Paritaprevir 16%
• Ombitasvir 16%
• Dasabuvir 16%
• Ritonavir 16%
• Grazoprevir 16%
• Elbasvir 16%
• Comorbidity 16%